^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models

Published date:
11/04/2021
Excerpt:
SNDX-50469 or SNDX-5613 treatment also exhibits impressive in vivo anti-AML efficacy in AML models expressing MLL-FP and NPM1c.
DOI:
10.1182/blood-2021-152060